GlassScriptPhysician profile
Melanie B Araujo
NPI 1295921120
$11,857.32
in general payments reported to CMS, 2019-2025
57 companies · $2,639 in 2025
The $2,639 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,541 · 2022: $2,556 · 2023: $2,617 · 2024: $2,505 · 2025: $2,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,720 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,720.35 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,668.86 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,433.37 | 2021-2025 | |
| Glaxosmithkline, LLC. | $697.16 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $625.03 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $536.09 | 2022-2025 | Rexulti |
| Ardelyx, INC. | $521.33 | 2023-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $505.32 | 2021-2025 | |
| Pfizer INC. | $409.23 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $390.76 | 2021-2025 | Verquvo, Gardasil 9, Capvaxive |
| Lilly USA, LLC | $351.48 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Phathom Pharmaceuticals, INC. | $337.12 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $310.12 | 2022-2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $302.42 | 2022-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $291.77 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.67 | 2021-2025 | Spiriva Respimat, Jardiance, Stiolto Respimat |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Araujo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.